高迁移率族蛋白B1与乳腺癌

doi:10.3760/cma.j.cn371439-20200414-00022

国际肿瘤学杂志 ›› 2020, Vol. 47 ›› Issue (5): 297-300.doi: 10.3760/cma.j.cn371439-20200414-00022

高迁移率族蛋白B1与乳腺癌

张艳强¹, 章阳¹(), 李春华², 张典平³, 刘保国¹, 彭显更¹

¹ 山东省聊城市人民医院乳腺甲状腺外科,山东第一医科大学(山东省医学科学院)252000
² 山东省聊城市东昌府区妇幼保健院手术麻醉科 252000
³ 山东省莘县第三人民医院神经内科 252427

收稿日期:2020-04-14 修回日期:2020-04-18 出版日期:2020-05-08 发布日期:2020-07-02
通讯作者: 章阳 E-mail:zhangyang5366@163.com

High mobility group protein B1 and breast cancer

Zhang Yanqiang¹, Zhang Yang¹(), Li Chunhua², Zhang Dianping³, Liu Baoguo¹, Peng Xiangeng¹

¹ Department of Breast and Thyroid Surgery, Liaocheng People's Hospital of Shandong Province, Shandong First Medical University & Shandong Academy of Medical Sciences, Liaocheng 252000, China;
² Department of Surgical Anesthesia, Dongchangfu Maternal and Child Health Hospital of Liaocheng, Shandong Province, Liaocheng 252000, China
³ Department of Neurology, Shenxian Third People's Hospital of Shandong Province, Shenxian 252427, China

Received:2020-04-14 Revised:2020-04-18 Online:2020-05-08 Published:2020-07-02
Contact: Zhang Yang E-mail:zhangyang5366@163.com

摘要/Abstract

摘要：

高迁移率族蛋白B1(HMGB1)是一类广泛存在于细胞内的核蛋白,当机体受到应激刺激时从细胞中释放或分泌,在细胞的存活/死亡途径中起关键作用。HMGB1具有巨大的生物学功能,是炎性疾病和肿瘤等重大疾病的主要调节因子。HMGB1与肿瘤细胞的增殖、分化、迁移、凋亡及耐药关系密切。随着对HMGB1研究的不断深入,发现其在乳腺癌的发生、发展、转移及耐药中扮演重要角色。结合HMGB1研究现状,探讨其在乳腺癌中的表达,可为临床探索新的治疗方案提供依据。

关键词: HMGB1蛋白质, 乳腺肿瘤, 肿瘤转移, 抗药性,肿瘤

Abstract:

High mobility group protein B1 (HMGB1) is a kind of nuclear protein widely existing in cells, which is released or secreted from cells by stress in the body and plays a key role in the survival or death pathways of cells. HMGB1 has a huge biological function and is the main regulator of major diseases such as inflammatory diseases and tumors. HMGB1 is closely related to the proliferation, differentiation, migration, apoptosis and drug resistance of tumor cells. With the continuous deepening of research on HMGB1, it is found that HMGB1 plays an important role in the occurrence, development, metastasis and drug resistance of breast cancer. Combined with the research status of HMGB1, the expression of HMGB1 in breast cancer is discussed to provide a new therapeutic scheme for clinical treatment.

Key words: HMGB1 protein, Breast neoplasms, Neoplasm metastasis, Drug resistance,neoplasm

张艳强, 章阳, 李春华, 张典平, 刘保国, 彭显更. 高迁移率族蛋白B1与乳腺癌[J]. 国际肿瘤学杂志, 2020, 47(5): 297-300.

Zhang Yanqiang, Zhang Yang, Li Chunhua, Zhang Dianping, Liu Baoguo, Peng Xiangeng. High mobility group protein B1 and breast cancer[J]. Journal of International Oncology, 2020, 47(5): 297-300.

参考文献 26

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. doi: 10.3322/caac.21492 pmid: 30207593
[2]	Van Rooijen JM, Qiu SQ, Timmer-Bosscha H, et al. Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2-positive breast cancer[J]. Eur J Cancer, 2018,103:52-60. DOI: 10.1016/j.ejca.2018.08.001. doi: 10.1016/j.ejca.2018.08.001 pmid: 30208359
[3]	Xu Y, Chen Z, Zhang G, et al. HMGB1 overexpression correlates with poor prognosis in early-stage squamous cervical cancer[J]. Tumour Biol, 2015,36(11):9039-9047. DOI: 10.1007/s13277-015-3624-7. doi: 10.1007/s13277-015-3624-7 pmid: 26084608
[4]	Reeves R. High mobility group (HMG) proteins: modulators of chromatin structure and DNA repair in mammalian cells[J]. DNA Repair (Amst), 2015,36:122-136. DOI: 10.1016/j.dnarep.2015.09.015. doi: 10.1016/j.dnarep.2015.09.015
[5]	Taniguchi N, Kawakami Y, Maruyama I, et al. HMGB proteins and arthritis[J]. Hum Cell, 2018,31(1):1-9. DOI: 10.1007/s13577-017-0182-x. doi: 10.1007/s13577-017-0182-x pmid: 28916968
[6]	Yang R, Zou X, Tenhunen J, et al. HMGB1 and extracellular histones significantly contribute to systemic inflammation and multiple organ failure in acute liver failure[J]. Mediators Inflamm, 2017,2017:5928078. DOI: 10.1155/2017/5928078. doi: 10.1155/2017/5928078 pmid: 28694564
[7]	张静娇, 邓春青. 与疾病相关的HMGB1基因多态性研究进展[J]. 国际生物医学工程杂志, 2019,42(4):357-361. DOI: 10.3760/cma.j.issn.1673-4181.2019.04.015.
[8]	Yun CW, Lee SH. The roles of autophagy in cancer[J]. Int J Mol Sci, 2018, 19(11). pii: E3466. DOI: 10.3390/ijms19113466.
[9]	Kumai T, Celis E, Rodriguez PC. Editorial: A matter of survival: HMGB1 regulates autophagy in tumor MDSC[J]. J Leukoc Biol, 2016,100(3):447-449. DOI: 10.1189/jlb.3CE0216-091R. doi: 10.1189/jlb.3CE0216-091R pmid: 27587376
[10]	Su Z, Ni P, She P, et al. Bio-HMGB1 from breast cancer contri-butes to M-MDSC differentiation from bone marrow progenitor cells and facilitates conversion of monocytes into MDSC-like cells[J]. Cancer Immunol Immunother, 2017,66(3):391-401. DOI: 10.1007/s00262-016-1942-2. doi: 10.1007/s00262-016-1942-2 pmid: 27987020
[11]	Zhao Y, Wu T, Shao S, et al. Phenotype, development, and biological function of myeloid-derived suppressor cells[J]. Oncoimmunology, 2016,5(2):e1004983. DOI: 10.1080/2162402x.2015.1004983. doi: 10.1080/2162402X.2015.1004983 pmid: 27057424
[12]	Wang H, Zou C, Zhao W, et al. Juglone eliminates MDSCs accumulation and enhances antitumor immunity[J]. Int Immunopharmacol, 2019,73:118-127. DOI: 10.1016/j.intimp.2019.04.058. doi: 10.1016/j.intimp.2019.04.058 pmid: 31085459
[13]	Wan W, Cao L, Khanabdali R, et al. The emerging role of HMGB1 in neuropathic pain: a potential therapeutic target for neuroinflammation[J]. J Immunol Res, 2016,2016:6430423. DOI: 10.1155/2016/6430423. doi: 10.1155/2016/6430423 pmid: 27294160
[14]	Bhat AA, Uppada S, Achkar IW, et al. Tight junction proteins and signaling pathways in cancer and inflammation: a functional crosstalk[J]. Front Physiol, 2018,9:1942. DOI: 10.3389/fphys.2018.01942. doi: 10.3389/fphys.2018.01942 pmid: 30728783
[15]	Ying S, Xiao X, Chen T, et al. PPAR ligands function as suppressors that target biological actions of HMGB1[J]. PPAR Res, 2016,2016:2612743. DOI: 10.1155/2016/2612743. doi: 10.1155/2016/2612743 pmid: 27563308
[16]	王超群, 黄必飞, 王艳, 等. 乳腺癌中高迁移率族蛋白B1蛋白表达及其临床病理意义[J]. 中华病理学杂志, 2020,49(1):57-61. DOI: 10.3760/cma.j.issn.0529-5807.2020.01.011.
[17]	Sharma AK, Sharma VR, Gupta GK, et al. Advanced glycation end products (AGEs), glutathione and breast cancer: factors, mechanism and therapeutic interventions[J]. Curr Drug Metab, 2019,20(1):65-71. DOI: 10.2174/1389200219666180912104342. doi: 10.2174/1389200219666180912104342 pmid: 30207227
[18]	Xiang L, Semenza GL. Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy[J]. Adv Cancer Res, 2019,141:175-212. DOI: 10.1016/bs.acr.2018.11.001. doi: 10.1016/bs.acr.2018.11.001 pmid: 30691683
[19]	Wang F, Sheng JF, Cai L, et al. The telomerase and alternative lengthening of telomeres mechanisms regulate laryngeal cancer cell apoptosis via the PI3K/Akt pathway[J]. ORL J Otorhinolaryngol Relat Spec, 2018,80(5-6):227-237. DOI: 10.1159/000489461. doi: 10.1159/000489461 pmid: 30212832
[20]	Shi Y, Zhang W, Ye Y, et al. Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway[J]. Cancer Biol Med, 2018,15(3):314-321. DOI: 10.20892/j.issn.2095-3941.2017.0188. doi: 10.20892/j.issn.2095-3941.2017.0188 pmid: 30197799
[21]	Choi AH, O'leary MP, Lu J, et al. Endogenous Akt activity promotes virus entry and predicts efficacy of novel chimeric orthopoxvi-rus in triple-negative breast cancer[J]. Mol Ther Oncolytics, 2018,9:22-29. DOI: 10.1016/j.omto.2018.04.001. doi: 10.1016/j.omto.2018.04.001 pmid: 29988465
[22]	Sharifi S, Barar J, Hejazi MS, et al. Doxorubicin changes Bax/Bcl-xL ratio, caspase-8 and 9 in breast cancer cells[J]. Adv Pharm Bull, 2015,5(3):351-359. DOI: 10.15171/apb.2015.049. doi: 10.15171/apb.2015.049 pmid: 26504757
[23]	Xu T, Jiang L, Wang Z. The progression of HMGB1-induced autophagy in cancer biology[J]. Onco Targets Ther, 2019,12:365-377. DOI: 10.2147/ott.S185876. doi: 10.2147/OTT.S185876 pmid: 30643434
[24]	Wang N, Yang B, Muhetaer G, et al. XIAOPI formula promotes breast cancer chemosensitivity via inhibiting CXCL1/HMGB1-mediated autophagy[J]. Biomed Pharmacother, 2019,120:109519. DOI: 10.1016/j.biopha.2019.109519. doi: 10.1016/j.biopha.2019.109519 pmid: 31629951
[25]	Nassar FJ, Nasr R, Talhouk R. MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction[J]. Pharmacol Ther, 2017,172:34-49. DOI: 10.1016/j.pharmthera.2016.11.012. doi: 10.1016/j.pharmthera.2016.11.012 pmid: 27916656
[26]	Sun Q, Liu T, Yuan Y, et al. MiR-200c inhibits autophagy and enhances radiosensitivity in breast cancer cells by targeting UBQLN1[J]. Int J Cancer, 2015,136(5):1003-1012. DOI: 10.1002/ijc.29065. doi: 10.1002/ijc.29065 pmid: 25044403

高迁移率族蛋白B1与乳腺癌

High mobility group protein B1 and breast cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 26

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[5]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[6]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[7]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[8]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[9]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[10]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[11]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[12]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[13]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[14]	杨丽蓉, 王羽丰. 预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[15]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.